| 词条 | Foliglurax |
| 释义 |
| Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = 4-[3-[4-nitroso-2-(5H-thieno[3,2-c]pyridin-6-ylidene)chromen-6-yl]propyl]morpholine | image = Foliglurax tautomer skeletal.svg | width = 250px | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = | CAS_supplemental = | class = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = 129320518 | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 59718537 | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = DT-1687; PXT-002331; PXT-2331 | C=23 | H=23 | N=3 | O=3 | S=1 | molecular_weight = 421.515 g/mol | SMILES = C1COCCN1CCCC2=CC3=C(C=C2)OC(=C4C=C5C(=CN4)C=CS5)C=C3N=O | StdInChI_Ref = | StdInChI = 1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,24H,1-2,6-10H2 | StdInChIKey_Ref = | StdInChIKey = XHRLGFLGWZIPEE-UHFFFAOYSA-N }}Foliglurax (developmental code names PXT-002331, DT-1687) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4) which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[1][2] As of July 2017, it is in phase II clinical trials for this indication.[1]{{Clear left}} References1. ^1 http://adisinsight.springer.com/drugs/800044176 2. ^{{cite journal|last1=Ellis|first1=J. Michael|last2=Fell|first2=Matthew J.|title=Current approaches to the treatment of Parkinson’s Disease|journal=Bioorganic & Medicinal Chemistry Letters|year=2017|issn=0960894X|doi=10.1016/j.bmcl.2017.07.075}} External links
6 : Chromenes|Experimental drugs|mGlu4 receptor agonists|Morpholines|Nitroso compounds|Thienopyridines |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。